AC Immune SA (ACIU)
NASDAQ: ACIU · IEX Real-Time Price · USD
3.480
-0.150 (-4.13%)
At close: Jul 19, 2024, 4:00 PM
3.500
+0.020 (0.57%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
AC Immune Revenue
AC Immune had revenue of $16.82M in the twelve months ending March 31, 2024, with 288.96% growth year-over-year. In the year 2023, AC Immune had annual revenue of $17.62M with 316.44% growth.
Revenue (ttm)
$16.82M
Revenue Growth
+288.96%
P/S Ratio
20.52
Revenue / Employee
$104,468
Employees
161
Market Cap
345.21M USD
Revenue Chart
* The company reports in CHF currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 17.62M | 13.39M | 316.44% |
Dec 31, 2022 | 4.23M | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 17.54M | -96.34M | -84.60% |
Dec 31, 2019 | 113.87M | 106.82M | 1,514.51% |
Dec 31, 2018 | 7.05M | -13.73M | -66.06% |
Dec 31, 2017 | 20.78M | -4.01M | -16.16% |
Dec 31, 2016 | 24.79M | -14.36M | -36.67% |
Dec 31, 2015 | 39.14M | 8.67M | 28.46% |
Dec 31, 2014 | 30.47M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ModivCare | 2.78B |
Nevro | 430.75M |
Vanda Pharmaceuticals | 177.60M |
Xeris Biopharma Holdings | 171.36M |
Talkspace | 162.13M |
Kamada | 149.55M |
ADC Therapeutics | 68.62M |
Cartesian Therapeutics | 25.91M |
ACIU News
- 7 weeks ago - AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 - GlobeNewsWire
- 2 months ago - Alzheimer's vaccine licensing deal boosts AC Immune - Market Watch
- 2 months ago - AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 2 months ago - AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease - Business Wire
- 4 months ago - AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 5 months ago - AC Immune Announces Upcoming Presentations at AD/PD™ 2024 - GlobeNewsWire
- 6 months ago - AC Immune to Regain Global Rights to Crenezumab and Semorinemab - GlobeNewsWire
- 7 months ago - AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases - GlobeNewsWire